Free Trial
NASDAQ:ALT

Altimmune Q2 2025 Earnings Report

Altimmune logo
$3.45 -0.07 (-1.99%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.47 +0.02 (+0.58%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

Altimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Altimmune Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Altimmune Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Altimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Altimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your email.

About Altimmune

Altimmune (NASDAQ:ALT), a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

View Altimmune Profile

More Earnings Resources from MarketBeat